No Cover Image

Journal article 229 views 36 downloads

Alzheimer's diagnosis beyond cerebrospinal fluid: Probe-Free Detection of Tau Proteins using MXene based redox systems and molecularly imprinted polymers

Arjun Ajith Mohan Orcid Logo, Sudhaunsh Deshpande, Tom Dunlop Orcid Logo, Beth Norman, Daniela Oliviera, Georgeta Vulpe, Felismina Moreira Orcid Logo, Sanjiv Sharma Orcid Logo

Biosensors and Bioelectronics: X, Volume: 20, Start page: 100513

Swansea University Authors: Arjun Ajith Mohan Orcid Logo, Tom Dunlop Orcid Logo, Georgeta Vulpe, Sanjiv Sharma Orcid Logo

  • 66925.VoR.pdf

    PDF | Version of Record

    © 2024 The Author(s). This is an open access article under the CC BY license.

    Download (5.44MB)

Abstract

Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI M...

Full description

Published in: Biosensors and Bioelectronics: X
ISSN: 2590-1370
Published: Elsevier BV 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa66925
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI MIP) for the sensitive detection of Tau-441 in interstitial fluid (ISF) and plasma. The VxPDA/PANI MIP sensor demonstrates a broad detection range of 5 fg/mL to 5 ng/mL (122 aM/L to 122 pM/L) in ISF without the use of redox mediators, with a lower limit of detection (LOD) of 2.3 fg/mL (60 aM/L). Furthermore, a handheld device utilizing this technology successfully detects Tau-441 in artificial serum with high sensitivity (5 fg/mL to 150 fg/mL (122 aM/L to 366 aM/L)) and specificity within a clinically relevant range. The rapid detection time (~32 minutes) and low cost (~£20/device) of this sensor highlight its potential for minimally invasive, early AD diagnosis in clinical settings. This advancement aims to facilitate a transition away from invasive cerebrospinal fluid (CSF)-based diagnostic techniques for AD.
Keywords: Alzheimer' disease, Tau protein, Biomarker
College: Faculty of Science and Engineering
Funders: The authors thank the MRC-AMED UK-Japan project (Multi-analyte prognostic and diagnostic screening in blood and skin for Alzheimer's disease, MR/X02153X/1) for their support. We also thank AIM providing SEM, EDS, and XPS facilities. AIM is funded in part by the EPSRC (EP/M028267/1), the European Regional Development Fund through the Welsh Government (80708) and the Welsh Government's Ser Cymru Program.
Start Page: 100513